A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 6, 2026 - P3 | N=358 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology
|